secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056848
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma reports Q1 2024 net loss $12.3M, cash $41M into Q1 2025
---------------------------------------------------------------------

- Collaboration revenue $1.7M vs $0.2M YoY; net loss $0.25/share vs $0.29.
- Cash and equivalents $41.0M at March 31, expected to fund operations into Q1 2025.
- CUE-101 abstract accepted for oral presentation at ASCO 2024; FDA meeting on registrational path.
- Preclinical CUE-401 (with Ono) and new CUE-500 series for autoimmune/inflammatory diseases.
- R&D expenses $10.2M, G&A $4.2M; net loss $12.3M for the quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000095017024056848/0000950170-24-056848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000095017024056848/cue-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer